Ikris Pharma Network
Ikris Pharma Network is a Noida, India-based pharmaceutical distributor founded in 2014 by Praveen Sikri, specializing in Named Patient Programs, clinical trial RLD sourcing, and international generic medicine exports to hospitals, importers, NGOs, and government health programs across more than 150 countries.
- Company typePrivate
- Founded2014
- HeadquartersNoida, India
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Ikris Pharma Network does
Ikris Pharma Network is a privately held pharmaceutical distribution and access company founded in August 2014 by Mr. Praveen Sikri and headquartered in Noida, India. The company specializes in three core service lines: (1) Named Patient Program management, providing legal pathways for patients in India, South Asia and other underserved markets to access unregistered or unavailable medicines, primarily for rare diseases, oncology and neurology; (2) Clinical Trial Sourcing, providing Reference Listed Drug and comparator supply for Indian CROs and global pharma companies running BA/BE studies and Phase I-IV trials; and (3) international wholesale export of Indian and Bulgarian generic and branded medicines to hospitals, importers, wholesalers, NGOs and government health programs across 150+ countries. Operations are supported by wholly-owned subsidiaries in Belgium (EU-GDP compliant certified pharmaceutical warehouse), Bulgaria (regional HQ and sourcing) and Hong Kong (regional HQ serving Asia), with compliance certifications spanning GDP, ISO, Pharmexcil, FSSAI and MSME.
The revenue model is a mix of transaction-based distribution margin on pharmaceutical product movement, professional services fees for Named Patient Program management and regulatory coordination, and managed services for clinical trial sourcing and comparator supply. Customer segments are horizontal across hospitals, importers/wholesalers, NGOs, government health programs and pharma/CRO buyers, with named partnerships covering eight originator innovators (BioMarin, PTC Therapeutics, Recordati Rare Diseases, Sarepta, Servier, Alexion, Santhera, Gilead). Proprietary technology is limited: a mobile application (Ikris Health+), WhatsApp business integration for B2B communication, and a databases-driven resource center; no API platform or AI/ML capabilities are disclosed. The company also owns and distributes a single branded specialty product, Triokris (Trientine Hydrochloride 250 mg) for Wilson's Disease, manufactured in a USFDA-approved facility.
Ownership is founder-led with no external private equity or venture capital investment disclosed; key domestic and international legal entities are wholly owned. The operating model is small-team (11–50 employees) with lean regional entities, relying on direct enterprise sales, government and NGO tenders, and partnership-driven Named-Patient Import channels. The company is positioned as a specialist intermediary between global originator innovators and emerging-market patients, leveraging regulatory expertise and cold-chain logistics rather than technology differentiation.
Ikris Pharma Network firmographics
Firmographics- Name
- Ikris Pharma Network
- Legal name
- Ikris Pharma Network Pvt. Ltd.
- Website
- https://ikrispharmanetwork.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Ikris Pharma Network is a Noida, India-based pharmaceutical distributor founded in 2014 by Praveen Sikri, specializing in Named Patient Programs, clinical trial RLD sourcing, and international generic medicine exports to hospitals, importers, NGOs, and government health programs across more than 150 countries.
- Ownership category
- akta.pro rank
Ikris Pharma Network industry classification
Industry- Product category
- Pharmaceutical Distribution
- NAICS
- Drugs and Druggists' Sundries Merchant Wholesalers (424210), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Services-Health Services (8000)
- akta.pro primary industry
- Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD)
- akta.pro secondary industries
- Third-Party Logistics (3PL) & Warehousing for Pharmaceuticals (HLAIAJAL), Specialty Pharmacy & Biologics Distribution (CRAOAHAD)
Keywords
Where Ikris Pharma Network is headquartered
LocationHeadquarters
- HQ city
- Noida
- HQ country
- India
- HQ region
- Asia
Offices5 records
Markets served
Ikris Pharma Network business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Distribution and Export: Ikris Pharma Network generates revenue through the export and distribution of pharmaceutical products including generic medicines, branded medicines, rare disease medicines, and specialty pharmaceuticals to hospitals, healthcare institutions, importers, wholesalers, NGOs, and government health programs across 150+ countries worldwide.
- Named Patient Program Services: Revenue generated from facilitating Named Patient Programs for patients requiring access to unregistered or unavailable medicines, including regulatory coordination, sourcing, and logistics services.
- Clinical Trial Sourcing Services: Services for pharmaceutical companies and CROs including Reference Listed Drug (RLD) sourcing, comparator drug supply, and clinical trial material logistics for BA/BE studies and Phase I-IV trials.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Transaction based/ take rate | Pay-as-you-go | B2B pharmaceutical distribution with quote-based pricing |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels5 records
Ikris Pharma Network product offering
Product offeringCore offering
Ikris Pharma Network is a pharmaceutical distribution and export company that sources, supplies, and delivers medicines across 150+ countries. Its core offerings include Named Patient Programs for accessing unregistered medicines, clinical trial sourcing of Reference Listed Drugs and comparators, international wholesale export of Indian generic and branded medicines, and Real World Data collection from Managed Access Programs. The company also distributes its own branded product Triokris (Trientine Hydrochloride) for Wilson's Disease and operates the Ikris Health+ mobile app providing global medicine database access.
Product overview
Ikris Pharma Network operates as a pharmaceutical services company offering a portfolio of interconnected services centered on medicine access and distribution. The core offerings include Named Patient Management (for accessing unapproved medicines), Clinical Trial Sourcing (RLD sourcing for pharmaceutical research), Indian Generic Medicines (global export of cost-effective generics), and Real World Data collection services. The company also manufactures and distributes its own branded product Triokris (Trientine Hydrochloride 250mg capsules) for Wilson's Disease treatment. An Ikris Health+ mobile app provides a global medicine database for patients and healthcare providers. Services span therapeutic areas including Oncology, Hepatology, Neurology, Transplant, Hematology, Immunology, Nephrology, and Rare Diseases.
Differentiator
Problem solved
Functional benefit
Brands
- Triokris: Trientine Hydrochloride Capsules USP 250 mg for Wilson's Disease treatment, manufactured in USFDA-approved facility and distributed by Ikris Pharma Network.
Products and services
- Triokris (Trientine Hydrochloride Capsules USP 250 mg) A copper-chelating agent indicated for the treatment of Wilson's Disease, especially in patients who cannot tolerate D-Penicillamine. Manufactured in a USFDA-approved facility and distributed by Ikris Pharma Network.
- Named Patient Management Service helping patients and healthcare providers access life-saving medications not available or registered in their home country through legal regulatory pathways. Covers major therapeutic areas including Oncology, Hepatology, Neurology, Transplant, Hematology, Immunology, and Nephrology.
- Clinical Trial Sourcing Provides Reference Listed Drug (RLD) sourcing and clinical trial supply services, handling procurement and logistics for medicines and comparators needed in drug development for research institutions and CROs. Includes temperature-sensitive study drug handling for BA/BE studies and Phase I-IV trials.
- Indian Generic Medicines Export Exporting medicinal products to over 150+ countries, delivering quality generic medicines from India to patients, hospitals, resellers, and pharmacies globally through established network with leading Indian manufacturers.
- Real World Data Collects Real-World Data (RWD) through Managed Access Programs for unlicensed or early-access therapies, providing insights for pharmaceutical companies, market access firms, regulators, and distributors.
- Ikris Health+ App Mobile application offering access to a wide range of medicines through a comprehensive global medicine database, providing essential medical information and support to patients and healthcare providers.
Quantifiable outcome
- Over 10,000 patients served with rare diseases and critical conditions
- +3 more outcomes
Companies that use Ikris Pharma Network
Customer profileNamed customers5 records
Segments5 records
Ideal customer profiles4 records
Ikris Pharma Network technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
Feature4 records
Ikris Pharma Network partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core.
- Santhera PharmaceuticalscoreIkris Pharma Network received official authorization from Santhera Pharmaceuticals to facilitate patient access to their medicines for Duchenne Muscular Dystrophy (DMD) in India. In 2025, Santhera signed an exclusive agreement appointing Ikris to manage the distribution of a DMD therapy in India. Access facilitated through Named-Patient Import pathway.
- Gilead SciencescoreIkris Pharma Network has been authorized by Gilead Sciences, Inc. to support patient access to specific therapies for HR+/HER2- metastatic breast cancer and metastatic triple-negative breast cancer in India. Access facilitated through Named-Patient Import pathway.
- BioMarin Pharmaceutical InccoreIkris Pharma Network is authorized by BioMarin to provide access to the company's medicines to Indian patients through Named-Patient Import. BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery, developing and commercializing targeted therapies that address the root cause of genetic conditions.
- PTC TherapeuticscoreIkris Pharma Network is authorized by PTC Therapeutics to provide access to their medicines to Indian patients through Named-Patient Import. PTC Therapeutics is a pharmaceutical company focused on developing treatments for rare diseases.
- Recordati Rare DiseasescoreIkris Pharma helps in accessing Recordati Rare Disease medicines for patients in India, Nepal, Pakistan & Sri Lanka through strategic alliances and exclusive distribution agreement. Patients from these countries can directly contact Ikris for Orphan Europe products.
- Sarepta TherapeuticscoreIkris Pharma Network is authorized by Sarepta Therapeutics to provide access to their medicines to Indian patients through Named-Patient Import. Sarepta Therapeutics is focused on advancing precision genetic medicine.
- Servier PharmaceuticalscoreIkris Pharma Network is authorized by Servier to provide access to their medicines to Indian patients through Named-Patient Import. Servier is dedicated to driving therapeutic progress.
- Alexion PharmaceuticalscoreIkris Pharma Network is authorized by Alexion Pharmaceuticals to provide access to Asfotase Alfa to Indian patients through Named-Patient Import basis. Every day builds a better tomorrow according to Alexion's mission.
Scale indicators7 records
Recent moves7 records
Expansion highlights5 records
Ikris Pharma Network competitors and assessment
Company assessmentBroad incumbents
- World Courier (Cencora): Part of Cencora (formerly AmerisourceBergen), World Courier provides specialty pharma logistics and cold-chain distribution globally; a scaled incumbent in the same logistics/cold-chain category Ikris operates in, albeit with much broader resources.
- Movianto (Owens & Minor): European pharmaceutical distribution and logistics specialist with cold-chain capability — comparable to Ikris's Belgium-based GDP-compliant distribution operation but at significantly larger scale.
- Almac Group: Global contract pharmaceutical services provider with clinical trial supply and distribution services — a larger incumbent offering overlapping capabilities in clinical trial supply and pharmaceutical services.
Direct peers
- Myoderm: US-based specialty pharmaceutical distributor focused on comparator sourcing and clinical trial supply — a direct functional peer in the RLD/comparator and clinical trial distribution segment.
- Clinigen Group: UK-headquartered global pharmaceutical services firm running Named Patient Programs, clinical trial supply, and unlicensed medicine access across multiple regions — the most direct functional comparison to Ikris's NPP and trial-sourcing franchise.
- Inceptua Group: Specializes in Named Patient Programs, early access, and clinical trial supply for pharma companies globally — overlaps directly with Ikris on NPP, RLD sourcing, and comparator supply.
- Trident Pharmaceuticals: Specialty pharmaceutical company providing Named Patient and managed access distribution, comparators and clinical supply services to pharma and biotech — a closer smaller-scale peer in the NPP/comparator niche.
Emerging players
- Caldic Life Sciences: Specialty distributor and solutions provider for life sciences including pharma raw materials and intermediates in Europe/Asia — partial overlap with Ikris on specialty pharma distribution and cold-chain solutions.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Ikris Pharma Network social profiles
Digital presenceIkris Pharma Network compliance and trust
Trust signalCompliance6 records
Ikris Pharma Network financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ikris Pharma Network leadership team
Management profileNumber of profiles
Profiles9 records
Ikris Pharma Network subsidiaries and ownership
Company hierarchySubsidiaries3 records
Ikris Pharma Network funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ikris Pharma Network M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ikris Pharma Network
What does Ikris Pharma Network do?
Ikris Pharma Network is a pharmaceutical distribution and export company that sources, supplies, and delivers medicines across 150+ countries. Its core offerings include Named Patient Programs for accessing unregistered medicines, clinical trial sourcing of Reference Listed Drugs and comparators, international wholesale export of Indian generic and branded medicines, and Real World Data collection from Managed Access Programs. The company also distributes its own branded product Triokris (Trientine Hydrochloride) for Wilson's Disease and operates the Ikris Health+ mobile app providing global medicine database access.
Is Ikris Pharma Network a public or private company?
Ikris Pharma Network is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Ikris Pharma Network founded?
Ikris Pharma Network was founded in 2014. It employs 51 to 100 people.
Where is Ikris Pharma Network based?
Ikris Pharma Network is headquartered in Noida, India, in the Asia region.
How does Ikris Pharma Network make money?
Three revenue lines are on record. Pharmaceutical Distribution and Export is the primary driver. The others are named Patient Program Services and clinical Trial Sourcing Services.
Who are Ikris Pharma Network's main competitors?
Broad incumbents on record are World Courier (Cencora), Movianto (Owens & Minor) and Almac Group. Direct peers are Myoderm, Clinigen Group, Inceptua Group and Trident Pharmaceuticals. Caldic Life Sciences is listed as an emerging player.
Does Ikris Pharma Network have an API?
No public API is recorded for Ikris Pharma Network.
What industry is Ikris Pharma Network in?
Ikris Pharma Network's product category is Pharmaceutical Distribution. Its primary akta.pro industry code is HLAGAMAD, Specialty Pharma & Biologics Distribution (GDP-compliant), with a secondary code of HLAIAJAL, Third-Party Logistics (3PL) & Warehousing for Pharmaceuticals. Its NAICS code is 424210 and its SIC code is 5122.